Matches in SemOpenAlex for { <https://semopenalex.org/work/W3112833100> ?p ?o ?g. }
- W3112833100 endingPage "3748" @default.
- W3112833100 startingPage "3748" @default.
- W3112833100 abstract "Liver fibrosis, a common hallmark of chronic liver disease (CLD), is characterized by the accumulation of extracellular matrix secreted by activated hepatic fibroblasts and stellate cells (HSC). Fibrogenesis involves multiple cellular and molecular processes and is intimately linked to chronic hepatic inflammation. Importantly, it has been shown to promote the loss of liver function and liver carcinogenesis. No effective therapies for liver fibrosis are currently available. We examined the anti-fibrogenic potential of a new drug (CM414) that simultaneously inhibits histone deacetylases (HDACs), more precisely HDAC1, 2, and 3 (Class I) and HDAC6 (Class II) and stimulates the cyclic guanosine monophosphate (cGMP)-protein kinase G (PKG) pathway activity through phosphodiesterase 5 (PDE5) inhibition, two mechanisms independently involved in liver fibrosis. To this end, we treated Mdr2-KO mice, a clinically relevant model of liver inflammation and fibrosis, with our dual HDAC/PDE5 inhibitor CM414. We observed a decrease in the expression of fibrogenic markers and collagen deposition, together with a marked reduction in inflammation. No signs of hepatic or systemic toxicity were recorded. Mechanistic studies in cultured human HSC and cholangiocytes (LX2 and H69 cell lines, respectively) demonstrated that CM414 inhibited pro-fibrogenic and inflammatory responses, including those triggered by transforming growth factor β (TGFβ). Our study supports the notion that simultaneous targeting of pro-inflammatory and fibrogenic mechanisms controlled by HDACs and PDE5 with a single molecule, such as CM414, can be a new disease-modifying strategy." @default.
- W3112833100 created "2020-12-21" @default.
- W3112833100 creator A5005462346 @default.
- W3112833100 creator A5016683081 @default.
- W3112833100 creator A5024344037 @default.
- W3112833100 creator A5031401964 @default.
- W3112833100 creator A5036616859 @default.
- W3112833100 creator A5043920475 @default.
- W3112833100 creator A5044992657 @default.
- W3112833100 creator A5048630412 @default.
- W3112833100 creator A5050719903 @default.
- W3112833100 creator A5063125997 @default.
- W3112833100 creator A5074181141 @default.
- W3112833100 creator A5079963965 @default.
- W3112833100 creator A5080496118 @default.
- W3112833100 creator A5081476843 @default.
- W3112833100 creator A5084083958 @default.
- W3112833100 creator A5085766415 @default.
- W3112833100 creator A5086940937 @default.
- W3112833100 date "2020-12-13" @default.
- W3112833100 modified "2023-10-18" @default.
- W3112833100 title "Dual Pharmacological Targeting of HDACs and PDE5 Inhibits Liver Disease Progression in a Mouse Model of Biliary Inflammation and Fibrosis" @default.
- W3112833100 cites W1824477449 @default.
- W3112833100 cites W1874881634 @default.
- W3112833100 cites W1964017399 @default.
- W3112833100 cites W1965842309 @default.
- W3112833100 cites W1967396537 @default.
- W3112833100 cites W1967895142 @default.
- W3112833100 cites W1969051655 @default.
- W3112833100 cites W1971701051 @default.
- W3112833100 cites W1971966651 @default.
- W3112833100 cites W1972138654 @default.
- W3112833100 cites W1975692560 @default.
- W3112833100 cites W1983094204 @default.
- W3112833100 cites W1998329843 @default.
- W3112833100 cites W2000369852 @default.
- W3112833100 cites W2000789410 @default.
- W3112833100 cites W2003189290 @default.
- W3112833100 cites W2006111363 @default.
- W3112833100 cites W2017387807 @default.
- W3112833100 cites W2021369251 @default.
- W3112833100 cites W2034380866 @default.
- W3112833100 cites W2039387726 @default.
- W3112833100 cites W2046056065 @default.
- W3112833100 cites W2054208176 @default.
- W3112833100 cites W2057095258 @default.
- W3112833100 cites W2057869883 @default.
- W3112833100 cites W2059114286 @default.
- W3112833100 cites W2060660978 @default.
- W3112833100 cites W2061213014 @default.
- W3112833100 cites W2062868961 @default.
- W3112833100 cites W2064959533 @default.
- W3112833100 cites W2066264051 @default.
- W3112833100 cites W2071074877 @default.
- W3112833100 cites W2071454387 @default.
- W3112833100 cites W2071937747 @default.
- W3112833100 cites W2072003502 @default.
- W3112833100 cites W2074496483 @default.
- W3112833100 cites W2076167801 @default.
- W3112833100 cites W2079819294 @default.
- W3112833100 cites W2082172262 @default.
- W3112833100 cites W2092233074 @default.
- W3112833100 cites W2094464744 @default.
- W3112833100 cites W2096083625 @default.
- W3112833100 cites W2096687216 @default.
- W3112833100 cites W2098453507 @default.
- W3112833100 cites W2099540110 @default.
- W3112833100 cites W2100157594 @default.
- W3112833100 cites W2102796116 @default.
- W3112833100 cites W2104193042 @default.
- W3112833100 cites W2109760090 @default.
- W3112833100 cites W2112351720 @default.
- W3112833100 cites W2117687222 @default.
- W3112833100 cites W2120753380 @default.
- W3112833100 cites W2125063590 @default.
- W3112833100 cites W2125608631 @default.
- W3112833100 cites W2126136540 @default.
- W3112833100 cites W2131352239 @default.
- W3112833100 cites W2131523161 @default.
- W3112833100 cites W2134116694 @default.
- W3112833100 cites W2134705170 @default.
- W3112833100 cites W2156044485 @default.
- W3112833100 cites W2157378178 @default.
- W3112833100 cites W2163268189 @default.
- W3112833100 cites W2165062244 @default.
- W3112833100 cites W2170029684 @default.
- W3112833100 cites W2171925512 @default.
- W3112833100 cites W2177007785 @default.
- W3112833100 cites W2225039922 @default.
- W3112833100 cites W2234390935 @default.
- W3112833100 cites W2263973560 @default.
- W3112833100 cites W2316351560 @default.
- W3112833100 cites W2324061288 @default.
- W3112833100 cites W2415541983 @default.
- W3112833100 cites W2470906679 @default.
- W3112833100 cites W2474201228 @default.
- W3112833100 cites W2475853404 @default.
- W3112833100 cites W2509283139 @default.